摘要
目的:初步评价11C-MET PET/CT脑显像临床应用价值。方法:研究对象为5例健康志愿者和36例脑部肿瘤患者,健康志愿者行11C-MET PET/CT脑显像,并作为对照组,36例脑部肿瘤患者中19例同时行11C-MET及18F-FDG PET/CT显像,17例仅行11C-MET PET/CT显像;结合健康对照组图像,对本组36例脑部肿瘤患者11C-MET PET/CT脑显像进行分析,并对同时进行18F-FDG PET显像者进行配对比较。结果:所有患者中11C-MET PET/CT显像阳性者30例,T/B均值为1.72±0.39,18F-FDG PET/CT显像阳性者9例,T/B均值为1.49±0.13。19例患者接受11C-MET PET/CT及18F-FDG PET/CT脑显像,T/B均值分别为1.64±0.49及1.16±0.36(t=3.33,P<0.01)。11C-MET PET/CT显像诊断脑肿瘤初诊患者灵敏度、特异度及准确度均为100%,其诊断脑肿瘤复发的灵敏度、特异度及准确度分别为94.7%(18/19)、100%(5/5)、95.8%(23/24)。结论:单独行11C-MET PET/CT脑显像可满足大多数脑肿瘤患者治疗前定位与治疗后疗效监测的需要;若与18F-FDG PET显像联合应用,更可能在肿瘤分级上获得帮助。
Objective ： To preliminarily evaluate the diagnostic value of ^11 C-MET PET/CT in brain tumors. Methods：. Five healthy volunteers and 36 brain tumor patients were involved in this study. ^11 C-MET PET/CT brain imaging was performed in 5 healthy volunteers and their results were designated as controls. All the 36 patients with brain tumors were examined with ^11 C-MET PET/CT, and among them, 19 of the cases were scanned with both ^11 C-MET and ^18 F-FDG PET/CT, Only ^11 C-MET PET/CT brain imaging was undergone in 17 of the patients. The findings of ^11 C-MET PET/CT imaging of the 36 brain tumor patients were comparatively analyzed with those of the healthy control group and at the same time the results of the 19 patients scanned with ^18F-FDG PET/CT were comparatively matched and studied. Results： In all 36 patients, positive ^11 C-MET PET/CT imaging was revealed in 30 of the cases with a mean T/B value of 1.72±0.39 and positive ^18 F-FDG PET/CT imaging was shown in 9 of the cases with a mean T/B value of 1.49±013, In the 19 patients scanned with both ^11C-MET PET/CT and ^18F-FDG PET/CT,the mean values of T/B were measured as 1.64±0. 49 and 1. 16± 0. 36 respectively （statistically,t= 3.3, P〈0.01）. The initial diagnostic sensitivity, specificity and accuracy rates of ^11 C- MET PET/CT imaging in brain tumors all showed 100% ; while its diagnostic sensitivity, specificity and accuracy rates in recurrent brain tumors revealed 94.7% （18/19）, 100% （5/5） and 95.8% （23/24） respectively. Conclusion： Clinically, in the cases of brain tumors most of the diagnostic requirements, such as pre-treatment tumor localization and post-treatment curing effect monitoring,could be fulfilled with a sole ^11C-MET PET/CT brain imaging. Most probably,the evaluation of the examination results of ^11 C-MET PET/CT brain imaging combining with those of ^18F-FDG PET/CT brain imaging would provided much help in tumor grading.
出处
《放射学实践》
2008年第2期208-211,共4页
Radiologic Practice
